Volume 24, Number 3—March 2018
Research Letter
Delftia tsuruhatensis, an Emergent Opportunistic Healthcare-Associated Pathogen
Table
Characteristics of 11 patients with Delftia tsuruhatensis infection, 2 from the literature and 9 from university hospitals in Marseille, France*
| Year, patient age, y/sex | Underlying conditions | Intravascular device | Specimen (description) | Clinical features; drug regimen | ID method; ID (score) | Amplification of 16 rDNA (similarity) | Ref |
|---|---|---|---|---|---|---|---|
| 2010, 53/F |
Metastatic breast cancer |
Yes |
Blood culture |
Port-related bacteremia with fever; ceftriaxone |
Phenotypic methods; Comamonas testosteroni |
D. tsuruhatensis (99%) |
(4) |
| 2012, 53/F |
Severe pulmonary hypertension |
Yes |
Blood culture |
Catheter-related bacteremia with chills; oral ciprofloxacin |
Phenotypic methods; D. acidovorans |
D. tsuruhatensis (100%) |
(5) |
| 2008, 77/M |
Liver cancer, colic adenocarcinoma |
Yes |
Bronchial aspirate (105 CFU/mL, pure) |
Considered by physicians as colonization |
Phenotypic methods; D. acidovorans |
D. tsuruhatensis (100%) |
Marseille hospitals (this study) |
| 2009, 70/F |
Unknown |
Unknown |
Bronchial aspirate (105 CFU/mL, pure) |
Not available |
MALDI-TOF MS; D. acidovorans (1.968) |
D. tsuruhatensis (99.9%) |
Marseille hospitals (this study) |
| 2010, 59/F |
Alcoholism, chronic end-stage renal failure |
Yes |
Blood culture |
Catheter-related bloodstream infection; piperacillin, tazobactam, gentamycin |
Not available |
D. tsuruhatensis (99.9%) |
Marseille hospitals (this study) |
| 2010, 6/M |
Cystic fibrosis |
No |
Sputum (103 CFU/mL, not pure) |
Not available |
MALDI-TOF MS; Arthrobacter castelli |
D. tsuruhatensis (99.1%) |
Marseille hospitals (this study) |
| 2013, 42/M |
Homeless, chronic renal failure, alcoholic hepatitis |
Yes |
Urine (106 CFU/mL, pure) |
Not available |
MALDI-TOF MS; D. tsuruhatensis (2.19) |
D. tsuruhatensis (99.8%) |
Marseille hospitals (this study) |
| 2014, 13/F |
Liver transplant |
Yes |
Blood cultures
(N = 2) |
Post-transplant fever; piperacillin, tazobactam |
Not available |
D. tsuruhatensis (99.9%) |
Marseille hospitals (this study) |
| 2015, 47/M |
Kidney transplant |
Yes |
Blood culture |
Fever |
MALDI-TOF MS; D. tsuruhatensis (2.38) |
Not performed |
Marseille hospitals (this study) |
| 2015, 82/M |
Hemodialysis, vascular dementia |
Yes |
Blood culture 1 |
Catheter-related bloodstream infection; ceftazidime |
MALDI-TOF MS; D. acidovorans (2.02) |
D. tsuruhatensis (100%) |
Marseille hospitals (this study) |
| Blood culture 2 |
MALDI-TOF MS; D. tsuruhatensis (2.21) |
D. tsuruhatensis (100%) |
|||||
| 2015, <1/F | Preterm birth | Yes | Respiratory sample 1 (107 CFU/mL) |
Ventilator-associated pneumonia; ceftazidime, second-line treatment with imipenem and amikacin | MALDI-TOF MS; D. tsuruhatensis (2.08) |
D. tsuruhatensis (99.9%) |
Marseille hospitals (this study) |
| Respiratory sample 2 (105 CFU/mL) | MALDI-TOF MS; D. acidovorans (2.21) | D. tsuruhatensis (100%) |
*Ref, reference; ID, identification; MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
1These authors contributed equally to this article.
Page created: February 16, 2018
Page updated: February 16, 2018
Page reviewed: February 16, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.